Plain-English translation of NCT07381803 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Researchers are testing whether fexofenadine hydrochloride, a medication commonly used to treat allergies, might also help protect the heart after a heart attack. You would receive either this medication or a placebo (a pill with no active ingredient) twice daily. The goal is to see whether the medication can improve how well your heart recovers and prevent complications in the months and years after your heart attack.
Heart attacks cause serious damage to the heart muscle, and doctors are always looking for new ways to protect patients during recovery. Early research suggests this medication might reduce inflammation and improve outcomes, so researchers want to test whether this treatment could help patients heal better after a heart attack.
You likely qualify if…
You likely don't qualify if…
You would take either the study medication or a placebo pill twice per day for the duration of the trial. You would attend regular visits for heart monitoring, blood tests, and ultrasounds to track how your heart is healing. The study involves approximately 2,804 participants and will track your recovery over time to see whether the medication helps improve your outcomes.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment target
~2,804 participants
Started
January 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Cheng Ni
Second Affiliated Hospital, School of Medicine, Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.